Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
The 2024 Platform Vision conference call will be hosted on
2024 Platform Vision Conference Call
The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section.
Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.
A live audio webcast of the presentation will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section.
Following each live audio webcast, a replay will be available on the Company's website for approximately 30 days.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for cancer treatment on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the
AlloCAR T™ is a trademark of
Allogene Media/Investor Contact:
EVP, Chief Corporate Affairs & Brand Strategy Officer
Source: Allogene Therapeutics, Inc.